AbbVie Inc. (NYSE:ABBV)

Pills

Short Sellers More Selective on Big Pharma Stocks

The short interest data has been released for the May 15 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: Ambarella, eBay, Rite Aid, TiVo, Yahoo, Valero, Virtu and More

Stocks were looking for a slightly positive opening on Wednesday, an effort to unseat recent market weakness. The one trend that is now nearly four years old is that investors ...
Read Full Story »
Eli Lilly Logo

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair share ...
Read Full Story »
Prescription drugs

Short Sellers Keep Strong Bets Against Big Pharma

The short interest data has been released for the April 30 settlement date. Pharmaceutical companies are usually involved in a lengthy process in getting their drug candidates to market through ...
Read Full Story »
Biotechnology word cloud

Huge Buyout Highlights 4 Deutsche Bank Biotech Focus Stocks

Combine the upcoming typical summer weakness with howls of a biotech bubble, and the recipe is in place for trouble, even for the top stocks in the industry. In a ...
Read Full Story »
Prescription drugs

Top Credit Suisse Major Pharma Stock Picks to Buy

Considering the health care sector has been on fire for the first quarter of 2015, analysts are putting more value in biotechs and big pharmaceuticals. Credit Suisse is no different. ...
Read Full Story »
95992888

5 Cheap Large Cap Stocks to Buy in an Expensive Stock Market

While the stock market clearly remains a better place for capital than the bond market, the reality is it is expensive. At 18 times earnings, it is pushing the envelope, ...
Read Full Story »
Pills

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

One thing investors look for in an aging bull market, especially one trading near all-time highs, is rising earnings. That is the only way to justify multiples that creep up ...
Read Full Story »
intelinside

Should Investors Buy These 4 ‘Bad News’ Stocks for Big Gains?

Often when a company presents bad news, it is for a real reason, and it may indeed be a harbinger of worse things to come. Sometimes, though, bad news is ...
Read Full Story »
Pills

The Next 3 Likely Biotech Buyout Candidates

One good way for a company to increase sales and move past simple organic growth is to make an acquisition, and that is just what AbbVie Inc. (NYSE: ABBV) did ...
Read Full Story »
462542665

Just How Expensive Is the Pharmacyclics Buyout?

Pharmacyclics Inc. (NASDAQ: PCYC) has seen its stock surge in the past week as rumors swirl about a potential acquisition. News finally broke late Wednesday that there was an official ...
Read Full Story »
pills

Is Express Scripts 2015 Guidance Good Enough For All-Time Highs?

After the markets closed Monday, Express Scripts Holding Company (NASDAQ: ESRX) reported its fourth-quarter financial results as $1.39 in earnings per share (EPS) and $26.31 billion in revenue. This is ...
Read Full Story »
Pfizer logo

Jefferies 4 Top Pharmaceutical Stocks to Buy

With the stock market hitting all-time highs, many investors are starting to wonder which sectors still hold value. Although seeming rich, the market continues climbing a wall of worry to ...
Read Full Story »
Pills

Neurocrine Biosciences Announces New Offering

Neurocrine Biosciences Inc. (NASDAQ: NBIX) has announced that it will have another public offering of its common stock. The total offering is expected to raise an aggregate of roughly $225 ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades: AbbVie, Alcoa, Apple, Deckers, Dish, Pfizer, Petrobras and More

Stocks were soft on Monday despite OPEC hinting at a faster oil demand recovery than expected. The rally from last week was on the heels of a bad January, and ...
Read Full Story »